EANS-News: november AG continues on its path to success/ Publication of the consolidated financial statements for the first half-year 2011

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Financial Figures/Balance Sheet/6-month report

Subtitle: • Increase in revenues to EUR 1,888 thousand
• Personnel and consultancy expenses fall by EUR 203 thousand
• Consolidated profit of EUR 39 thousand despite special item for AGM
• Earnings per share (EPS) EUR 0.01
• Equity in positive figures at EUR 96 thousand
• Liabilities significantly reduced and placed on a long-term basis

Cologne (euro adhoc) - August 18, 2011: november AG, the
Cologne-based company listed in the Prime Standard index of the
German Stock Exchange under securities identification No. WKN A0Z24E
has today announced its half-year result for the 2011 fiscal year.

Key results for the first half-year of 2011: With effect from January
1, 2011, PROGEN Biotechnik GmbH of Heidelberg and Multimetrix GmbH of
Regensburg have acquired the personnel and laboratory equipment of
MICROBIONIX GmbH of Regensburg as part of an asset deal. The
companies are thus broadening their product portfolio in the field of
Luminex technologies to include services hitherto offered by
MICROBIONIX such as testing services, bead coupling and sample
testing on customer demand. PROGEN Biotechnik GmbH now exclusively
distributes the PATHFAST® analyzing system of Mitsubishi Chemical
Europe GmbH in Germany. The PATHFAST® analyzing system allows
quantitative and reliable measurements from heparin or EDTA whole
blood or plasma in emergency medicine (myocardial infarction,
myocarditis). PROGEN Biotechnik GmbH has extended the field of
application of its well-established Hantavirus Hantaan IgG & IgM
ELISA for serological diagnosis of hantavirus infections. The new
hantavirus diagnostics test now allows the serotype Dobrava to be
diagnosed in one test along with the serotype Hantaan. The former
subsidiaries "PROGEN BIOTECHNIQUE S.a.r.l." and "november Caribe
Inc." have been wound up. The Annual General Meeting was held in
Cologne on May 17, 2011. The adopted annual financial statements for
2010 were presented and explained. The Management Board and the
Supervisory Board were granted discharge for their actions during the
year and UHY were confirmed as Auditors.

Summary of the financial result for the first half-year of 2011:
Consolidated revenues rose from EUR 1,806 thousand (first half-year
of 2010) to EUR 1,888 thousand. At the same time, personnel costs and
other operating expenses such as legal and consultancy expenses fell
by EUR 203 thousand. Consequently, the operating result improved
significantly on the comparative period in 2010, rising from EUR -425
thousand to EUR 24 thousand; the year-on-year comparison would have
been even better if the costs of this year´s AGM had not been
incurred in the first half of the year. The consolidated operating
results of the individual companies PROGEN Biotechnik GmbH,
Multimetrix GmbH and november AG also showed a marked improvement in
the first half-year of 2011 compared with the same period in 2010.
For example, PROGEN Biotechnik GmbH´s revenues rose from EUR 1,788
thousand (first half-year of 2010) to EUR 1,843 thousand, while
Multimetrix GmbH´s revenues rose from EUR 11 thousand to EUR 42
thousand. PROGEN Biotechnik GmbH´s operating result also rose from
EUR 27 thousand (first half-year of 2010) to EUR 388 thousand, while
Multimetrix GmbH´s operating result rose from EUR -177 thousand to
EUR 4 thousand. The costs of the early AGM meant that november AG´s
operating result fell from EUR -275 thousand in the first half-year
of 2010 to EUR -318 thousand in 2011. In addition to the
balance-sheet improvements, the Group´s financial burdens due to
outstanding loans were also significantly reduced by EUR 1,679
thousand to EUR 1,500 thousand (2010: EUR 3,179 thousand). The terms
and also the repayment of these liabilities were in most cases
extended to twelve years, producing a reduction in non-current
liabilities from loans to EUR 391 thousand. The monthly burden on the
Company´s liquidity is therefore very small.

The sole member of the Managing Board of november AG, Dr. Dirk Zurek,
commented as follows on november AG´s pleasing performance: "During
the first half of 2011 PROGEN in particular demonstrated very
positive performance. For PROGEN, 2010 was still characterized by the
restructuring process, certification and re-alignment, but in 2011
the first new developments and new areas of business began to emerge,
along with initial strategic measures. The expansions of business
that have taken place this year are already having an impact on
results. International business has also developed extremely
favorably, largely due to international marketing via the new
Internet shop and Internet marketing activities. PROGEN is once again
acting as a link between science and industry and is positioning
itself on the market with its core competence of successful, expert
commercialization of scientific developments. For example, PROGEN
performs standard-compliant production in accordance with industrial
standards, arranges registration for different markets and advisory
sales. To extend the required scientific network, different research
projects are already being discussed in detail and in different
configurations by science and industry. This is creating the
foundations for new areas of business and new product lines which
will significantly expand PROGEN´s portfolio in the near future. New
appointments are also currently ensuring that PROGEN´s expertise is
enhanced accordingly. Multimetrix also revealed a significant
improvement in its result, not least due to the two new employees and
the services they offer. The asset deal with Microbionix is therefore
already having a positive effect on results. The decline in november
AG´s result for the first half of 2011 is in particular due to the
fact that the costs of the early AGM are already included in the
figures for the first half-year. november AG´s individual result is
EUR 43 thousand down on the same period in the previous year. But
since this is significantly less than the overall costs of the AGM,
it is clear that without the costs of the early AGM, the individual
result for november AG also shows an improvement on 2010. In
particular, there was a further marked reduction in necessary
external consultancy expenses. Some of these are still attributable
to existing issues such as the clarification of fiscal matters from
2007, etc. To ensure november AG is still able to fulfill the duties
and obligations associated with its listing in the Prime Standard
index, the Management Board´s stated aim is to cover basic necessary
resources through its own employees. november AG´s lean
organizational structure is supported by external consultants only
where required; this approach and also the creation of synergies
between the individual companies reflect a high level of cost
awareness. These combined factors mean november AG remains on course
for success."

The full financial statements for the first half-year of 2011 are now
available at www.november.eu/investor-relations/reports/

november AG november AG is an investment and holding company, listed
in the prime standard of the regulated German Stock Exchange
(Deutsche Börse) with special focus on medical technology,
biotechnology and environmental technology. www.november.eu

PROGEN Biotechnik GmbH PROGEN Biotechnik GmbH, Heidelberg, is an EN
ISO 13485:2007 certified manufacturer of in vitro diagnostics (e.g.
Lyme Disease, Hantavirus, FSME) and research reagents (e.g.
antibodies, polypeptides, AAV, hyperphage). www.progen.de

Multimetrix GmbH Multimetrix GmbH develops and manufactures multiplex
tests/assays based on the Luminex® technology for applications in
diagnostics (infectious disease serology/Borrelia) and in research
(HPV genotyping, coated beads) and offers test/contract services and
technical support for the Luminex® Analyzer. www.multimetrix.com

Further inquiry note:
Dr. Dirk Zurek
Vorstand/CEO
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: november Aktiengesellschaft
Hansaring 97
D-50670 Köln
phone: +49(0)221-82005 20-10
FAX: +49(0)221-82005 20-15
mail: info@november.de
WWW: http://www.november.de
sector: Biotechnology
ISIN: DE000A0Z24E9
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Stuttgart, Düsseldorf, Hannover, München
language: English